Natco Pharma Ltd has got the final USFDA approval for the generic version of Vidaza (Azacitidine for injection, 100 mg per vial), single-dose vial. Natco and its marketing partner Breckenridge Pharmaceutical, Inc. (BPI) plans to launch the product in the US market in the near future. The drug Vidaza by Celgene Corporation is a prescription anti-cancer chemotherapy drug that is indicated to treat, myelodysplastic syndrome (MDS) and has a total combined sales of $188 million for the 12-month period ended April 2017, based on industry sales data.
Company Profile : Natco Pharma Ltd
Leave a Reply